Beam Therapeutics Inc. BEAM
We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. 10-K, Item 1
- Headquarters
- Cambridge, MA
- CEO
- John M. Evans
- Next results
- around Jan 11, 2027
BEAM among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
24 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 24, 2026 against Feb 25, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 8 checks found nothing to note
-
Cash from operations lower than net incomeCash from operations −$345.1M vs net income −$80.0M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: Deloitte & Touche LLP
7 more checks with nothing to note
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No longer listed: Revenue Recognition. Same as last year: Research and Development Estimates
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
24 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
The terms of our financing agreement with Sixth Street Lending Partners and our indebtedness could adversely affect our operations and limit our ability to plan for or respond to changes in our business. If we are unable to comply with restrictions in the financing agreement, the repayment of our existing indebtedness could be…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
As we are initially seeking to identify and develop product candidates to treat diseases using novel technologies, there is heightened risk that the FDA, the EMA or other regulatory authority may not consider the clinical trial endpoints that we propose to provide clinically meaningful results. Even if the endpoints are deemed…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
For example, on September 9, 2025, the President issued a memorandum directing HHS to “ensure transparency and accuracy in DTC prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $60.9M | $377.7M | $63.5M | $139.7M |
| Net income | −$289.1M | −$132.5M | −$376.7M | −$80.0M |
| Operating cash flow | $22.5M | −$149.2M | −$347.2M | −$345.1M |
| Free cash flow | −$26.4M | −$182.9M | −$356.2M | −$360.0M |
Revenue, FY2019 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$139.7M ▲ 120.0% in FY2025−$80.0M in FY2025−$360.0M in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 3, 2026Bethany Cavanagh (Senior Vice President, Finance) adopted a 10b5-1 trading plan reported in the 10-Q, up to 25,904 shares, runs to Sep 17, 2027
-
8-KNov 3, 2026Quarterly results 8-K item 2.02
-
10-QNov 3, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Beam Therapeutics Inc., Cambridge, MA · from the 10-K filed Feb 24, 2026
We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities. Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA.
- Headquarters
- Cambridge, MA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 3, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BEAM/export.csv") into a cell.